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Abstract
Introduction Iron-deWciency anaemia during pregnancy
and postpartum occurs frequently and may lead to severe
maternal and foetal complications. New treatment regimens
include intravenous iron administration in particular clinical
situations. The aim of the study was to determine optimal
diagnostic and therapeutic approaches to iron-deWciency
anaemia during pregnancy and postpartum.
Methods The evidence from data available from pub-
lished studies and recommendations regarding diagnosis
and treatment were reviewed. As conclusions, recommen-
dations are given by an expert panel.
Results During pregnancy, oral iron therapy is given as
Wrst-line treatment. In cases with lack of eYcacy, unwar-
ranted side eVects or very low haemoglobin values, intrave-
nous iron treatment with iron carboxymaltose is a
preferable alternative, although data regarding safety are
limited. In the postpartum period, haemoglobin values less
than 95 g/L are treated ideally by intravenous carboxymal-
tose, leading to more rapid haemoglobin recovery.
Conclusion New intravenous iron preparations such as
iron carboxymaltose have an excellent eYcacy, side eVect
proWle and advantages as compared to oral iron prepara-
tions for particular clinical indications.
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Introduction
Anaemia is one of the most common problems in obstet-
rics. It is well known that, depending on its severity, anae-
mia constitutes an important risk factor in both maternal
and foetal morbidity. If the mother suVers from iron-deW-
ciency anaemia, the risks to the foetus include a higher rate
of premature birth, intrauterine growth retardation, unfa-
vourable impact on placental development, and reduced
neonatal iron stores. Maternal risks include depleted blood
reserves during delivery and thus an increased risk of an
allogeneic blood transfusion in case of signiWcant blood
loss, cardiovascular stress, anaemia symptoms (fatigue,
reduced physical and mental capacities, headaches, ortho-
static dizziness, exhaustion, prolonged hospitalizations,
decreased milk production in the puerperium, depleted
maternal iron stores postpartum and subsequently. For
these reasons, the eYcient treatment of anaemia following
its diagnosis has a positive impact on maternal as well as
foetal outcomes. One main focus is on reducing or at best
avoiding the need for an allogeneic blood transfusion, as a
result of an adequate anaemia treatment prior to delivery. In
the following, the primary focus is on the treatment and not
on the prophylaxis of iron-deWciency anaemia.
Anaemia in pregnancy
Diagnosis
The lower threshold value for haemoglobin in pregnant
women is deWned as Hb <110 g/L in the Wrst and last tri-
mester and <105 g/L in the second trimester (CDC 1998).
An Hb level, <105 g/L thus, indicates anaemia at any stage
during pregnancy, requiring diagnostic clariWcation and
Expert Panel Recommendation, Quality Assurance Commission of the 
Swiss Society of Obstetrics and Gynecology.
C. Breymann · C. Honegger · W. Holzgreve · D. Surbek (&)
University Women’s Hospital, 
Inselspital EYngerstr. 102, 3010 Bern, Switzerland
e-mail: qsk-sggg@insel.ch123
578 Arch Gynecol Obstet (2010) 282:577–580treatment because of its association with an increased risk
of intrauterine growth retardation and premature birth. For
diagnostic clariWcation, the Wrst tests to be performed
should be a red blood count and a serum ferritin assay. As a
rule, determining the serum ferritin level is suYcient for the
diagnosis of iron-deWciency anaemia: a value of <15 g/L
provides clear evidence for iron-deWciency anaemia. For
normal and/or elevated serum ferritin levels, other causes
have to be investigated (e.g. haemoglobinopathies, such as
-thalassaemia, sickle cell anaemia, anaemia of infection,
haemorrhagic anaemia, vitamin B12 or folic deWciency,
etc.). Determining the serum ferritin level in addition to the
haemoglobin level at the beginning of pregnancy may be a
good strategy. If ferritin is <30 g/L, there is a 90% cer-
tainty that iron stores are depleted, even if there is no indi-
cation as yet of anaemia. In these cases, iron substitution
during pregnancy is indicated. Caution: as part of an
inXammatory response, serum ferritin can be “false nor-
mal” or “false high”, as it reacts in the same way as an
acute phase protein. For that reason, the recommendation is
to determine the CRP level at the same time as ferritin lev-
els. In the following cases, the advice is to perform a hae-
moglobin electrophoresis or a haemoglobin chromatography
(HPLC high-performance liquid chromatography) to iden-
tify -thalassaemia or another haemoglobinopathy as the
cause of the anaemia: (1) positive family case history of the
pregnant woman or her partner, (2) anaemia without iron
deWciency (ferritin level normal), (3) MCV (erythrocyte
mean corpuscular volume) level of <70 fL and an MCH
(mean corpuscular haemoglobin) level of <27 pg (caution:
Hb electrophoresis can be normal for -thalassaemia) and
(4) depending on ethnicity (caution: blood count for sickle
cell anaemia without pathological Wndings). In case of a
proven—usually heterozygous—haemoglobinopathy, the
partner also has to be examined and the option of invasive
prenatal diagnostics oVered, if a relevant risk to the foetus
exists.
Treatment
The choice of treatment depends on the cause of the anae-
mia, i.e. generally iron deWciency. The primary treatment
for mild cases of iron-deWciency anaemia (Hb 90–105 g/L)
is a peroral iron therapy (iron II salts or iron III polymal-
tose) in doses of 160–200 mg/day (ideally on an empty
stomach (iron II salts), fractionated). The same also applies
to depleted iron stores at the beginning of pregnancy (ferri-
tin <30 g/L) without anaemia, because of the additional
requirement for iron in the course of the pregnancy.
A switch to an intravenous iron preparation is advanta-
geous in a number of cases, including: a lack of response to
oral iron (Hb levels rising by less than 10 g/L within
14 days), lack of compliance, intolerance of oral iron prepa-
rations (gastrointestinal side eVect), severe, advanced or
progressive anaemia (Hb < 90 g/L), desire for rapid anae-
mia treatment (advanced gestational age, Jehovah’s witness
and many more). Several studies have shown that intrave-
nous iron therapy is superior to oral iron treatment with
respective indications. In addition, the gastrointestinal side
eVects of the oral iron therapy can be avoided.
Iron III saccharate (Venofer®)
The iron III saccharate complex has been proven world-
wide as a safe and very well-tolerated iron preparation. It is
approved for administration in pregnancy from the second
trimester onwards, with a general rate of side eVects below
0.5%. Venofer® should only be infused in institutions
equipped for cardiopulmonary resuscitation. The maximum
dose of parenteral iron III saccharate is 200 mg per applica-
tion, preferably diluted in 100 mL 0.9% NaCl solution
administered as infusion. The solution is infused over a
period of approximately 30 min through an intravenous
access (caution: rapid infusion bears the risk of a hypoten-
sive reaction). Depending on the baseline Hb level, these
intravenous applications are to be repeated 1–3 times a
week, until an Hb level of >105 g/L has been achieved. The
patient can then be switched to oral iron substitution for
maintenance. Iron overloading is not expected.
Iron carboxymaltose (Ferinject®)
Iron carboxymaltose (Ferinject®) is a new non-dextran iron
complex with the advantage that it can be administered in
high doses of up to 1,000 mg/administration over a short
period of time (15–30 min per infusion). This makes it pos-
sible to avoid costly repeat infusions of small intravenous
iron quantities at a good level of tolerance, probably match-
ing that of iron III saccharate. In line with iron III saccha-
rate, the preparation is also approved for administration
during pregnancy from the second trimester onwards. To
date (as for iron III saccharate), there are no large-scale ran-
domized studies on foetal safety during pregnancy; for that
reason, prior to giving any intravenous iron preparation, it is
necessary to evaluate the risk/beneWt ratio carefully even in
the second and third trimester. In a placental perfusion
model, iron carboxymaltose has been shown not to cross the
placental barrier to the foetal side (Malek 2009). Iron carb-
oxymaltose is administered as a rapid infusion over 15–
30 min or as a bolus injection over 1–2 min (not SC or IM!).
As a rapid infusion, iron carboxymaltose can be adminis-
tered as a single dose of up to 1,000 mg iron or, respectively,
15 mg/iron/kg body weight (up to the level of the desired
total dose); the maximum dose for intravenous bolus admin-
istration is 200 mg. Higher doses if required (>1,000 mg)
need to be fractionated and administered at 7-day intervals.123
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(Reveiz, Gyte and Cuervo, 2007, CD 003094), there is no
clear recommendation as to the choice of treatment of iron-
deWciency anaemia during pregnancy. The administration of
parenteral iron results in a faster increase in haemoglobin
levels than the oral administration, countered, though, by a
lack of data regarding the safety of parenteral iron in respect
of thromboses and severe allergic reactions. In addition, the
data from 17 studies are insuYcient to assess the beneWt in
respect of maternal and foetal treatment outcomes. However,
this updated does not include recent studies on the eYcacy
and safety of iron saccharate in pregnancy.]
There are no large-scale studies for either preparation
(iron carboxymaltose and iron III saccharate) with respect
to foetal safety.
Postpartum anaemia
Diagnosis
An Hb level <100 g/L is seen as a clinically signiWcant
postpartum anaemia. This is usually a combination of
haemorrhagic anaemia and in some instances pre-existing
iron-deWciency anaemia. The decision on Hb control during
the puerperium is to be taken into consideration of the
blood loss and the clinical state of the puerpera (symptoms
of anaemia). In addition of relevance is the prepartum Hb
level. The nadir of the postpartum Hb level is reached
approximately 48 h after the primary plasma volume distri-
bution. The additional determination of the ferritin level in
the puerperium does not make sense, because for the Wrst
6 weeks after delivery, both a “false normal” and a “false
high” reading may be present (see above: ferritin = acute
phase protein). The iron stores of puerperia can be assessed
before delivery or from about 6 weeks after. There is no
point in determining ferritin levels in cases of combined
pre- and postpartum anaemia, because depleted iron stores
can safely be assumed. Parenteral iron treatment without
prior ferritin assessment can be dangerous, although, in
cases of haemochromatosis (heterozygote frequency 1:10).
Treatment
The treatment depends on the severity of the anaemia and
the puerperia’s state of health. As a rule, the recommended
treatment for mild anaemia with an Hb of 95–120 g/L is the
peroral administration of iron of approximately 80–200 mg
(iron II salts or iron III polymaltose). In case of bad (gastro-
intestinal) tolerance of the peroral iron therapy, the intrave-
nous administration of iron is a good alternative. For
moderately severe (Hb < 95 g/L) to severe anaemia
(Hb < 85 g/L), the parenteral administration of iron is an
important alternative to the oral one. Several studies
showed an advantage of the parenteral administration of
iron III saccharate when compared with orally administered
iron. One study even showed that the introduction of paren-
teral iron III saccharate to treat anaemia led to a reduction
in allogeneic blood transfusion within the study collective.
The maximum dose of parenteral iron III saccharate is
200 mg per application, preferably diluted in 100 mL 0.9%
NaCl solution as an infusion. The solution is infused over a
period of approximately 30 min through an intravenous
access (caution: infusing too rapidly bears the risk of a
hypotensive reaction). Depending on the baseline Hb level,
these intravenous applications are to be repeated 2–3 times
a week, until an Hb level of >100 g/L has been achieved.
The patient can then be switched to oral iron substitution
for maintenance. Iron overloading is not expected. Within
14 days, levels are expected to increase by 30 g/L. At the
end of the observation period, puerperia treated with paren-
teral iron III saccharate have higher ferritin levels than
women who received oral treatment, and thus probably also
persistently higher iron stores. This is particularly beneW-
cial in a quick succession of pregnancies.
The new preparation Iron carboxymaltose (Ferinject®)
has already been tested in several randomized multicentre
studies in comparison with oral iron substitution for the
treatment of postpartum anaemia and demonstrated an out-
standing safety proWle comparable to that of iron III saccha-
rate, combined with great eVectiveness. In three of the four
studies, the intravenous administration of iron carboxymal-
tose for the treatment of postpartum anaemia showed supe-
riority in eYcacy to oral iron therapy, while one study
showed intravenous iron carboxymaltose to be equal to oral
therapy over 12 weeks. The safety proWle has to be rated as
very high and comparable to that of iron saccharate. The
dosage is the same as described above. Practical beneWts,
patient comfort and the reduction in cost associated with a
single administration support the advantage of iron carb-
oxymaltose over iron III saccharate.
In cases of severe anaemia (<80 g/L), the administration
of recombinant erythropoietin (rhEPO) in addition to par-
enteral iron carboxymaltose may be considered. According
to the Cochrane database, the administration of rhEPO can
support the treatment of anaemia, but only in conjunction
with parenteral iron, to avoid an ineVective erythropoiesis.
Erythropoietin (rhEPO) should only be given in cases of
severe anaemia combined with additional factors (pro-
nounced clinical symptoms, rejection of donor blood, etc.).
A sample dose is, e.g. 150 IE/kg bodyweight once a day
SC, a total of four doses of epoietin alpha (Eprex®) in addi-
tion to the parenteral treatment with iron carboxymaltose.
Consideration also has to be given to the fact that the
administration of rhEPO is an oV-label use with consider-
able associated costs.123
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transfusion has to be considered is at approximately 60 g/L,
but depends on the clinical symptoms. A decision on an
allogeneic blood transfusion should always be made on an
individual basis giving full consideration to the patient’s
wishes. There is no general threshold value (e.g. Hb
60 g/L = blood transfusion), but consideration has to be
given to inapparent complications, e.g. indications of silent
myocardial ischaemia.
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